Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 98

1.

Older patients with myeloma derive similar benefit from autologous transplantation.

Sharma M, Zhang MJ, Zhong X, Abidi MH, Akpek G, Bacher U, Callander NS, Dispenzieri A, Freytes CO, Fung HC, Gale RP, Gasparetto C, Gibson J, Holmberg LA, Kindwall-Keller TL, Klumpp TR, Krishnan AY, Landau HJ, Lazarus HM, Lonial S, Maiolino A, Marks DI, Mehta P, Mikhael Med JR, Nishihori T, Olsson R, Ramanathan M, Roy V, Savani BN, Schouten HC, Scott E, Tay J, To LB, Vesole DH, Vogl DT, Hari P.

Biol Blood Marrow Transplant. 2014 Nov;20(11):1796-803. doi: 10.1016/j.bbmt.2014.07.013. Epub 2014 Jul 18.

2.

Hematopoietic cell transplant comorbidity index is predictive of survival after autologous hematopoietic cell transplantation in multiple myeloma.

Saad A, Mahindra A, Zhang MJ, Zhong X, Costa LJ, Dispenzieri A, Drobyski WR, Freytes CO, Gale RP, Gasparetto CJ, Holmberg LA, Kamble RT, Krishnan AY, Kyle RA, Marks D, Nishihori T, Pasquini MC, Ramanathan M, Lonial S, Savani BN, Saber W, Sharma M, Sorror ML, Wirk BM, Hari PN.

Biol Blood Marrow Transplant. 2014 Mar;20(3):402-408.e1. doi: 10.1016/j.bbmt.2013.12.557. Epub 2013 Dec 14.

3.

Autologous Hematopoietic Cell Transplantation in Patients With Multiple Myeloma: Effect of Age.

Dhakal B, Nelson A, Guru Murthy GS, Fraser R, Eastwood D, Hamadani M, Pasquini M, D'Souza A, Hari P.

Clin Lymphoma Myeloma Leuk. 2017 Mar;17(3):165-172. doi: 10.1016/j.clml.2016.11.006. Epub 2016 Nov 25.

PMID:
28159578
4.

Race and outcomes of autologous hematopoietic cell transplantation for multiple myeloma.

Hari PN, Majhail NS, Zhang MJ, Hassebroek A, Siddiqui F, Ballen K, Bashey A, Bird J, Freytes CO, Gibson J, Hale G, Holmberg L, Kamble R, Kyle RA, Lazarus HM, LeMaistre CF, Loberiza F, Maiolino A, McCarthy PL, Milone G, Omondi N, Reece DE, Seftel M, Trigg M, Vesole D, Weiss B, Wiernik P, Lee SJ, Rizzo JD, Mehta P.

Biol Blood Marrow Transplant. 2010 Mar;16(3):395-402. doi: 10.1016/j.bbmt.2009.11.007. Epub 2009 Nov 14.

5.

Autologous hematopoietic cell transplantation for multiple myeloma patients with renal insufficiency: a center for international blood and marrow transplant research analysis.

Mahindra A, Hari P, Fraser R, Fei M, Huang J, Berdeja J, Callander N, Costa L, Diaz MA, Freytes C, Gale RP, Girnius S, Holmberg L, Kharfan-Dabaja M, Kumar S, Kyle R, Lazarus H, Lee C, Maiolino A, Moreb J, Nishihori T, Pawarode A, Saad A, Savani BN, Schriber J, William B, Wirk BM, Krishnan A, Nieto Y, D'Souza A.

Bone Marrow Transplant. 2017 Dec;52(12):1616-1622. doi: 10.1038/bmt.2017.198. Epub 2017 Sep 18.

6.

Transplantation related toxicity and mortality in older autologous hematopoietic cell transplantation recipients.

Belete H, Burns LJ, Shanley R, Nayar M, McClune B, Lazaryan A, Bachanova V, Bejanyan N, Ustun C, Brunstein C, Weisdorf DJ, Arora M.

Am J Hematol. 2017 Sep;92(9):E529-E533. doi: 10.1002/ajh.24814. Epub 2017 Jul 19.

7.

Autologous/Allogeneic Hematopoietic Cell Transplantation versus Tandem Autologous Transplantation for Multiple Myeloma: Comparison of Long-Term Postrelapse Survival.

Htut M, D'Souza A, Krishnan A, Bruno B, Zhang MJ, Fei M, Diaz MA, Copelan E, Ganguly S, Hamadani M, Kharfan-Dabaja M, Lazarus H, Lee C, Meehan K, Nishihori T, Saad A, Seo S, Ramanathan M, Usmani SZ, Gasparetto C, Mark TM, Nieto Y, Hari P.

Biol Blood Marrow Transplant. 2018 Mar;24(3):478-485. doi: 10.1016/j.bbmt.2017.10.024. Epub 2017 Oct 24.

8.

Association of Socioeconomic Status with Outcomes of Autologous Hematopoietic Cell Transplantation for Multiple Myeloma.

Hong S, Rybicki L, Abounader D, Bolwell BJ, Dean R, Gerds AT, Hamilton BK, Hill BT, Jagadeesh D, Kalaycio M, Liu HD, Pohlman B, Sobecks R, Majhail NS.

Biol Blood Marrow Transplant. 2016 Jun;22(6):1141-1144. doi: 10.1016/j.bbmt.2016.03.011. Epub 2016 Mar 16.

9.

Trends in autologous hematopoietic cell transplantation for multiple myeloma in Europe: increased use and improved outcomes in elderly patients in recent years.

Auner HW, Szydlo R, Hoek J, Goldschmidt H, Stoppa AM, Morgan GJ, Moreau P, Attal M, Marit G, Russell N, Brune M, Cook G, Sonneveld P, Schönland S, Garderet L, Kröger N.

Bone Marrow Transplant. 2015 Feb;50(2):209-15. doi: 10.1038/bmt.2014.255. Epub 2014 Nov 10.

PMID:
25387088
10.

Nonmyeloablative unrelated donor hematopoietic cell transplantation to treat patients with poor-risk, relapsed, or refractory multiple myeloma.

Georges GE, Maris MB, Maloney DG, Sandmaier BM, Sorror ML, Shizuru JA, Lange T, Agura ED, Bruno B, McSweeney PA, Pulsipher MA, Chauncey TR, Mielcarek M, Storer BE, Storb R.

Biol Blood Marrow Transplant. 2007 Apr;13(4):423-32. Epub 2007 Feb 1.

11.

Salvage second hematopoietic cell transplantation in myeloma.

Michaelis LC, Saad A, Zhong X, Le-Rademacher J, Freytes CO, Marks DI, Lazarus HM, Bird JM, Holmberg L, Kamble RT, Kumar S, Lill M, Meehan KR, Saber W, Schriber J, Tay J, Vogl DT, Wirk B, Savani BN, Gale RP, Vesole DH, Schiller GJ, Abidi M, Anderson KC, Nishihori T, Kalaycio ME, Vose JM, Moreb JS, Drobyski W, Munker R, Roy V, Ghobadi A, Holland HK, Nath R, To LB, Maiolino A, Kassim AA, Giralt SA, Landau H, Schouten HC, Maziarz RT, Mikhael J, Kindwall-Keller T, Stiff PJ, Gibson J, Lonial S, Krishnan A, Dispenzieri A, Hari P; Plasma Cell Disorders Working Committee of the Center for International Blood and Marrow Transplant Research.

Biol Blood Marrow Transplant. 2013 May;19(5):760-6. doi: 10.1016/j.bbmt.2013.01.004. Epub 2013 Jan 5.

12.

Disparities in utilization of autologous hematopoietic cell transplantation for treatment of multiple myeloma.

Costa LJ, Huang JX, Hari PN.

Biol Blood Marrow Transplant. 2015 Apr;21(4):701-6. doi: 10.1016/j.bbmt.2014.12.024. Epub 2014 Dec 30.

14.

Busulfan, Melphalan, and Bortezomib versus High-Dose Melphalan as a Conditioning Regimen for Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma.

Rodriguez TE, Hari P, Stiff PJ, Smith SE, Sterrenberg D, Vesole DH.

Biol Blood Marrow Transplant. 2016 Aug;22(8):1391-1396. doi: 10.1016/j.bbmt.2016.03.021. Epub 2016 May 7.

15.

Autologous haematopoietic cell transplantation in elderly patients with multiple myeloma.

Auner HW, Garderet L, Kröger N.

Br J Haematol. 2015 Nov;171(4):453-62. doi: 10.1111/bjh.13608. Epub 2015 Jul 27. Review.

PMID:
26213240
16.

Simplified validated prognostic model for progression-free survival after autologous transplantation for hodgkin lymphoma.

Hahn T, McCarthy PL, Carreras J, Zhang MJ, Lazarus HM, Laport GG, Montoto S, Hari PN.

Biol Blood Marrow Transplant. 2013 Dec;19(12):1740-4. doi: 10.1016/j.bbmt.2013.09.018. Epub 2013 Oct 3.

17.

Outcome after autologous and allogeneic stem cell transplantation for patients with multiple myeloma: impact of graft-versus-myeloma effect.

Alyea E, Weller E, Schlossman R, Canning C, Mauch P, Ng A, Fisher D, Gribben J, Freeman A, Parikh B, Richardson P, Soiffer R, Ritz J, Anderson KC.

Bone Marrow Transplant. 2003 Dec;32(12):1145-51. Review.

PMID:
14647268
18.

Autologous/reduced-intensity allogeneic stem cell transplantation vs autologous transplantation in multiple myeloma: long-term results of the EBMT-NMAM2000 study.

Gahrton G, Iacobelli S, Björkstrand B, Hegenbart U, Gruber A, Greinix H, Volin L, Narni F, Carella AM, Beksac M, Bosi A, Milone G, Corradini P, Schönland S, Friberg K, van Biezen A, Goldschmidt H, de Witte T, Morris C, Niederwieser D, Garderet L, Kröger N; EBMT Chronic Malignancies Working Party Plasma Cell Disorders Subcommittee.

Blood. 2013 Jun 20;121(25):5055-63. doi: 10.1182/blood-2012-11-469452. Epub 2013 Mar 12.

19.

Use of matched unrelated donors compared with matched related donors is associated with lower relapse and superior progression-free survival after reduced-intensity conditioning hematopoietic stem cell transplantation.

Ho VT, Kim HT, Aldridge J, Liney D, Kao G, Armand P, Koreth J, Cutler C, Ritz J, Antin JH, Soiffer RJ, Alyea EP.

Biol Blood Marrow Transplant. 2011 Aug;17(8):1196-204. doi: 10.1016/j.bbmt.2010.12.702. Epub 2010 Dec 27.

20.

Early failure of frontline rituximab-containing chemo-immunotherapy in diffuse large B cell lymphoma does not predict futility of autologous hematopoietic cell transplantation.

Hamadani M, Hari PN, Zhang Y, Carreras J, Akpek G, Aljurf MD, Ayala E, Bachanova V, Chen AI, Chen YB, Costa LJ, Fenske TS, Freytes CO, Ganguly S, Hertzberg MS, Holmberg LA, Inwards DJ, Kamble RT, Kanfer EJ, Lazarus HM, Marks DI, Nishihori T, Olsson R, Reddy NM, Rizzieri DA, Savani BN, Solh M, Vose JM, Wirk B, Maloney DG, Smith SM, Montoto S, Saber W, Alpdogan O, Cashen A, Dandoy C, Finke R, Gale R, Gibson J, Hsu JW, Janakiraman N, Laughlin MJ, Lill M, Cairo MS, Munker R, Rowlings PA, Schouten HC, Shea TC, Stiff PJ, Waller EK.

Biol Blood Marrow Transplant. 2014 Nov;20(11):1729-36. doi: 10.1016/j.bbmt.2014.06.036. Epub 2014 Jul 5.

Supplemental Content

Support Center